BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
Evaluation of the therapeutic effect and dose-effect of Bifidobacterium breve on the primary Clostridioides difficile infected mice. ✅
Go to Publication ✅
Applied microbiology and biotechnology (Appl Microbiol Biotechnol ) Vol: 105 Issue 24 Pages: 9243-9260 Pub: 2021 Dec Epub: 2021 Nov 9 Authors Yang J , Yang H , |
|
|
Clinical Efficacy of Probiotics for Allergic Rhinitis: Results of an Exploratory Randomized Controlled Trial. ✅
Go to Publication ✅
Nutrients (Nutrients ) Vol: 16 Issue 23 Pages: Pub: 2024 Nov 30 Epub: 2024 Nov 30 Authors Lungaro L , Malfa P , Manza F , Costanzini A , Valentini G , Squarzanti DF , Viciani E , Velichevskaya A , Castagnetti A , Barbalinardo M , Gentili D , Cariani A , Ghisellini S , Caputo F , De Giorgio R , Caio G , |
|
|
Bifidobacterium breve B2798 and Its Heat-Killed Cells Alleviate Inflammation in Rats with DSS Model by Modulating Gut Microbiota. ✅
Go to Publication ✅
Probiotics and antimicrobial proteins (Probiotics Antimicrob Proteins ) Vol: Issue Pages: Pub: 2025 Sep 5 Epub: 2025 Sep 5 Authors Feng C , Zhao Y , He Q , Yu J , Sun Z , |
|
|
Amelioration of cognitive and behavioral damage by Bifidobacterium breve 05 via regulation of BDNF/NeuN and LPS/Iba1/aß expression. ✅
Go to Publication ✅
International journal of food sciences and nutrition (Int J Food Sci Nutr ) Vol: Issue Pages: 1-16 Pub: 2025 Nov 17 Epub: 2025 Nov 17 Authors Zhou S , Ma X , Nie H , Mu G , Wu X , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
